To be added to the scientific events notification list, please click here.
Please join us for our next free public lecture, Clinical Trials and Collaboration in Parkinson’s Disease, on Tuesday, April 20, 2021. This informative event will be hosted virtually and will feature presentations and a Q&A session with international Parkinson’s disease experts.
For the millions of people around the world with Parkinson’s, treatments that slow or stop disease progression are desperately needed. One promising approach to find such therapies is drug repurposing — rigorously evaluating medications for other diseases, such as diabetes, as potential treatments for Parkinson’s. The foremost initiative in this area is the International Linked Clinical Trials, a program spearheaded by Cure Parkinson’s in collaboration with Van Andel Institute that brings together some of the world’s leading Parkinson’s scientists, clinicians and advocates to clinically evaluate whether existing medications can impede Parkinson’s progression.
Please note, this event takes place in Eastern Standard Time (GMT-5)
Dr. Patrik Brundin investigates molecular mechanisms in Parkinson’s disease, and his goals are to develop new therapies aimed at slowing or stopping disease progression or repairing damage. He is one of the top-cited researchers in the field of neurodegenerative disease and leads international efforts to repurpose drugs to treat Parkinson’s.
Dr. Simon Stott is the Deputy Director of Research at Cure Parkinson’s, an international supporter of both lab- and clinic-based research on Parkinson’s. Originally from New Zealand, Dr. Stott has over 15 years of experience in the field of Parkinson’s research — in both the academic and biotech sectors. He has been involved in lab-based research as well as clinical studies, with a number of scientific publications. He also maintains the Science of Parkinson’s website, which attempts to explain in plain English the research currently being conducted on Parkinson’s.
Dr. Richard Wyse joined Cure Parkinson’s in 2007 as its Director of Research and Development. He is currently engaged in a unique program of worldwide basic and clinical research in the development of radical new pharmaceutical and regenerative treatments for Parkinson’s disease, including a major global initiative (International Linked Clinical Trials initiative) involving repositioning drugs into clinical trials to determine patient benefits of a large number of different therapeutics in specialist neurology hospitals around the world.
Contact Sarah Rollman at 616.234.5712 or via email for more information or to become an event sponsor.